Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Chemotherapy and Chemoradiation in T4 Rectal Cancer
NCT00070434Phase 2Withdrawn
- Sponsor
- SWOG Cancer Research Network
- Start
- Aug 2004
- Primary completion
- Feb 2006
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
01
Overview
Phase 2, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, oxaliplatin, fluorouracil and capecitabine in rectal cancer (3 arms), sponsored by SWOG Cancer Research Network. Primary endpoints: Feasibility of obtaining pre-treatment determination of intratumoral molecular markers, Response probability to induction chemotherapy at 8 weeks and 2 more. Planned start Aug 2004; status: withdrawn.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumaboxaliplatinfluorouracilcapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00070434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00070434.